Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Lexicon Pharmaceuticals (NASDAQ: LXRX ) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Lexicon and see what CAPS investors are saying about the stock right now.
Lexicon facts
| Headquarters (founded) | The Woodlands, Texas (1995) |
| Market Cap | $1.2 billion |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $1.1 million |
| Management | Co-Founder/CEO Arthur Sands |
| Return on Equity (average, past 3 years) | (43.8%) |
| Cash/Debt | $222.8 million / $23.5 million |
| Competitors | Aptalis Pharma |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 21% of the 63 All-Star members who have rated Lexicon believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those Fools, All-Star zzlangerhans, touched on the stock's seemingly unsustainable valuation:
If there's one thing recent history has told us about Lexicon, it's that a market cap of over a billion for their highly speculative pipeline will not hold. Lexicon has assets, to be sure, and at a market cap of [$500M] or even [$600M] in this frothy market you wouldn't be hearing anything about them from me. But LX4211 doesn't have a clear place in the rapidly evolving field of glycemic control, and progression to phase III is on hold as a partnership is awaited. Telotristat is in the early stages of what undoubtedly will be a long phase III trial for the narrow indication of carcinoid. If the last year's pattern holds, the share price will be well under [$2 per share] again before any positive catalysts emerge from the pipeline.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
No comments:
Post a Comment